1. Volume 124, Issue 3, Pages 642-650 (March 2003)
Interferon-α 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: A randomized study 
Didier Samuel, Thierry Bizollon, Cyrille Feray, Bruno Roche, Si Nafa Si Ahmed, Catherine Lemonnier, Marielle Cohard, Michel Reynes, Michelle Chevallier, Christian Ducerf, Jacques Baulieux, Michael Geffner, Janice K. Albrecht, Henri Bismuth, Christian Trepo 
Gastroenterology 
Volume 124, Issue 3, Pages (March 2003)
DOI: /gast
Copyright © 2003 American Gastroenterological Association Terms and Conditions

2. Fig. 1
Flow chart of the selection process of the 2 groups of patients. HCC, hepatocellular carcinoma; ductopenia, loss of more than 25% interlobular bile ducts at screening biopsy.
Gastroenterology  , DOI: ( /gast )
Copyright © 2003 American Gastroenterological Association Terms and Conditions

3. Fig. 2
Mean changes in serum HCV RNA from baseline expressed in log10 for patients treated with interferon alfa-2b plus ribavirin as well as control patients. The mean baseline value of HCV RNA in the treated and control groups was 6.81 ± 1.07 and 6.38 ± 0.81, respectively. The mean decrease in HCV RNA was −2.76 ± 1.58, −2.88 ± 1.86; −2.82 ± 2.16, and −1.38 ± 2.16, respectively, at weeks 12, 24, and 48 and at the end of follow-up. There was no change in mean HCV RNA levels in the control group (+0.02, −0.11, 0.00, and −0.25, respectively, at weeks 12, 24, and 48 and at the end of follow-up). The mean decrease in log10 HCV RNA level was significant at all time points (P < at all time points and P = 0.04 at the end of follow-up). ●, treatment; ○, control.
Gastroenterology  , DOI: ( /gast )
Copyright © 2003 American Gastroenterological Association Terms and Conditions

4. Fig. 3
Mean changes in HCV RNA from baseline among patients treated with interferon alfa-2b plus ribavirin who were HCV RNA negative (●) and HCV RNA positive (○) at week 24.
Gastroenterology  , DOI: ( /gast )
Copyright © 2003 American Gastroenterological Association Terms and Conditions